Hypoxia, Normoxia, Hyperoxia
Conditions
Keywords
Oxygen, Hypoxia, Hyperoxia, Inflammation, Innate immunity
Brief summary
Oxygen is a widely available gas that is cheap, easy to get and extensively used in medicine. From animal studies it has become apparent that increasing or lowering the degree of oxygen in the blood, the inflammatory response can be altered. We will investigate of this is also true in humans by increasing, lowering or keeping oxygen levels normal while giving healthy subjects a short inflammatory stimulus.
Detailed description
The primary objective of the study is to determine the effects of hyperoxia and hypoxia compared to normoxia in the human endotoxemia model on the innate immune reponse in healthy volunteers. A parallel, randomized study in healthy male volunteers. The subjects will be randomized to hypoxia, hyperoxia, or normoxia, and will all undergo experimental human endotoxemia (administration of 2 ng/kg LPS iv). In the hypoxia group: the subjects will breathe an individualized mix of nitrogen and room air for 3.5 hours using an air-tight respiratory helmet. The gas mixture will be adjusted to achieve a saturation of 80-85%. In the hyperoxia group, subjects will breathe 100% oxygen for 3.5 hours using the same respiratory helmet. In the normoxia group, subjects will breathe room air (21% oxygen, 79% nitrogen) also wearing the respiratory helmet. 1 hour after oxygen status adjustment (t=0), all subject will be administered an intravenous bolus (2ng/kg) of LPS derived from E coli O:113. 2.5 hours after LPS administration, the helmets will be removed and all subjects will breathe ambient room air. The primary study endpoint is the difference in plasma cytokines between the hypoxia and normoxia group, and between the hyperoxia and normoxia group. Secondary objectives include HIF-1α protein and mRNA, aHIF mRNA expression in circulating leukocytes, measures of ROS, leukocyte phagocytosis, and cytokine production by leukocytes stimulated ex vivo with various inflammatory stimuli, and measurement of basic hemodynamic and ventilatory parameters and temperature.
Interventions
LPS is used to elicit an inflammatory response in all subjects
Sponsors
Radboud University Medical Center
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 35 Years
Healthy volunteers
Yes
Inclusion criteria
* Written informed consent to participate in this trial * Male subjects aged 18 to 35 years inclusive * Healthy as determined by medical history, physical examination, vital signs, 12-lead electrocardiogram, and clinical laboratory parameters
Exclusion criteria
* Use of any medication(including herbal remedies and vitamin/mineral supplements) or recreational drugs within 7 days prior to profiling day * Smoking * Use of caffeine, or alcohol or within 1 day prior to profiling day * Previous participation in a trial where LPS was administered * Surgery or trauma with significant blood loss or blood donation within 3 months prior to profiling day * Participation in another clinical trial within 3 months prior to profiling day. * History, signs or symptoms of cardiovascular disease * An implant that in the opinion of the investigator may make invasive procedures risky for the subject due to the increased risks associated with a possible infection. * Subject has an implanted active cardiac device (ICD, IPG and/or CRT) Implanted active neurostimulation device * Subject has internal jugular vein that cannot be accessed * History of vaso-vagal collapse or of orthostatic hypotension * History of atrial or ventricular arrhythmia * Resting pulse rate ≤45 or ≥100 beats / min * Hypertension (RR systolic \>160 or RR diastolic \>90) * Hypotension (RR systolic \<100 or RR diastolic \<50) * Conduction abnormalities on the ECG consisting of a 1st degree atrioventricular block or a complex bundle branch block * Subject is diagnosed with epilepsy or history of seizures * Renal impairment: plasma creatinine \>120 μmol/L * Liver function abnormality: alkaline phosphatase\>230 U/L and/or ALT\>90 U/L * Coagulation abnormalities: APTT or PT \> 1.5 times the reference range * History of asthma * Immuno-deficiency CRP \> 20 mg/L, WBC \> 12x109/L, or clinically significant acute illness, including infections, within 2 weeks before profiling day * Known or suspected of not being able to comply with the trial protocol - Inability to personally provide written informed consent (e.g. for linguistic or mental reasons) and/or take part in the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Plasma TNF-alpha concentration following LPS administration | 1 day | Plasma TNF-α concentration after LPS administration (Area Under Curve); comparison of subjects treated with hypoxia compared to normoxia and hyperoxia compared to hypoxia |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Hepcidin and iron parameters | 1 day | — |
| catecholamines and cortisol | 1 day | adrenaline, noradrenaline, dopamine and cortisol |
| Neutrophilic function | 1 day | — |
| body temperature | 1 day | — |
| oxygen saturation and arterial blood gas | 1 | — |
| subjective symptom scores | 1 day | — |
| high sensitive troponine | 1 day | — |
| iFABP | 1 day | — |
| brain specific proteins | 1 day | — |
| endocan | 1 day | — |
| downstream targets of HIF | 1 day | adrenomedullin, VEGF, EPO |
| Hypoxia Inducible Factor 1 alpha in circulating leukocytes | 1 day | Hypoxia Inducible Factor 1 alpha in circulating neutrophils, lymfocytes and monocytes as measured with flow cytometry |
| Hypoxia Inducible Factor mRNA and anti Hypoxia Inducible Factor mRNA in circulating leukocytes | 24 hours | — |
| cognitive function | 1 day | neuropsychologic assessment of cognitive function |
| Phagocytic function of circulating leukocytes | 1 day | — |
| cytokine production after ex vivo stimulation of leukocytes | 1 day | — |
| circulating cytokines (including but not limited to IL-6, IL-10, IL-1RA) | 1 day | — |
| Hemodynamic parameters | 1 day | Blood pressure, heart frequency, cardiac output measurement |
| ventilatory response | 1 day | Measures of ventilation: respiratory rate, blood gas changes |
| adenosine metabolism | 1 day | urine and plasma adenosine,adenosine receptor mRNA, purines |
| alkaline phosphatase | 1 day | — |
| heart rate variability | 1 day | — |
| kidney injury markers in plasma and urine | 2 days | — |
| microbiome in feces | -1 day untill 1 week | — |
| markers of immunoparalysis | 1 day | monocytic histone 3 lysine 4 trimethylation of the promotor region of pro-inflammatory genes, ex viv production of proinflammatory cytokines, HLA-DR expression on moncytes. |
| measures of coagulation and plateletfunction | 1 day | platelet activation and platelet function, thrombin generation and other coagulation parameters, hematolocial infection profile using hematology analyser |
| meausures of coagulation and fibrinolysis | 1 day | thrombin generation, thrombocyte function, ROTEM, plasmatic coagulation, fibrinolysis parameters |
| Reactive Oxygen Species in circulating leukocytes | 1 day | — |
Countries
Netherlands
Outcome results
None listed